Phase II clinical study of HLA-A*2402-restricted survivin-derived peptide vaccine therapy for patients with recurrent non-muscle-invasive bladder cancer
Phase 2
Recruiting
- Conditions
- bladder cancer
- Registration Number
- JPRN-UMIN000005819
- Lead Sponsor
- Sapporo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Coexistence of other malignancy 2) Immunodeficiency or history of splenectomy 3) Intake of steroids or immunosuppressants 4) Severe heart disease, active infection, coagulation disorder 5) Under anticoagulant therapy 6) Pregnant woman 7) Lactating woman 8) Hope to have a children 9) No willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures 10) History of severe drug allergy 11) History of severe drug-induced hepatic or renal dysfunction
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence-free survival
- Secondary Outcome Measures
Name Time Method Induction of epitope-specific T cell immunity